Ertuvia-S 5/100mg Tablet

Ertuvia-S 5/100mg Tablet is a combination medication containing two active ingredients: Empagliflozin & Metformin. Empagliflozin belongs to a class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors, while Metformin is a biguanide antidiabetic agent. This combination is used for the management of type 2 diabetes mellitus (T2DM) in adults. Empagliflozin works by inhibiting SGLT2 in the kidneys, thereby reducing glucose reabsorption and increasing urinary glucose excretion. Metformin works by decreasing hepatic glucose production and improving insulin sensitivity, leading to reduced blood glucose levels.

Uses:

1. Type 2 Diabetes Mellitus (T2DM): Ertuvia-S 5/100mg Tablet is indicated for the treatment of T2DM in adults. It helps to improve glycemic control by lowering blood glucose levels through complementary mechanisms of action. This combination medication is typically prescribed for patients whose blood sugar is not adequately controlled with diet and exercise alone, or who require dual therapy with both Empagliflozin and Metformin.

Side Effects:

While Ertuvia-S 5/100mg Tablet is generally well-tolerated, it may cause side effects in some individuals. Common side effects associated with Empagliflozin and Metformin include:

• Nausea and Vomiting: Some patients may experience nausea and vomiting, particularly at the beginning of treatment. Taking the medication with food can help alleviate these symptoms.
• Diarrhea: Diarrhea is a common side effect of Metformin and may occur in some individuals. Maintaining adequate hydration and dietary adjustments can help manage diarrhea.
• Genital Infections: Empagliflozin may increase the risk of genital infections, such as yeast infections in women and balanitis in men. Patients should maintain good hygiene practices and promptly seek medical attention if symptoms occur.
• Hypoglycemia: Hypoglycemia (low blood sugar) may occur, particularly in combination with other antidiabetic medications or insulin. Patients should be educated about the signs and symptoms of hypoglycemia and how to manage it.

Precautions:

• Renal Function: Ertuvia-S 5/100mg Tablet should be used with caution in patients with impaired renal function, as both Empagliflozin and Metformin are excreted by the kidneys. Renal function should be assessed before starting treatment and periodically thereafter.
• Hepatic Function: Patients with hepatic impairment should use Ertuvia-S 5/100mg Tablet with caution, as Metformin is primarily eliminated by the liver. Liver function tests should be monitored regularly.
• Heart Failure: Empagliflozin has been shown to reduce the risk of cardiovascular events in patients with T2DM and established cardiovascular disease. However, it should be used with caution in patients with heart failure, and therapy should be carefully monitored.